VISION-DMD

Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy

Patient Group Funders

Preclinical funding and Phase 1 clinical trials were supported by DMD foundations:

                                                  Print

 

                                                       

 

                                                          

 

                                                           

 

                                         

 

For more information about Reveragen’s business model click here

Follow us on twitter

EUFlag2020

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 667078.

To find out more about the project contact us at [email protected]